Nakashima Toshihisa, Kiba Takayoshi, Ogawa Yoshikazu, Kimura Akiko, Kido Miki, Okikawa Yoshiko, Ito Takuo, Saito Akihisa, Hosokawa Atsuko, Shintani Hiromi, Okada Yuko, Taniguchi Takako, Taniyama Kiyomi, Kozawa Kazuhiro, Niimi Hiromasa
Department of Pharmacy, National Hospital Organization Kure Medical Center and Chugoku Cancer Center.
Gan To Kagaku Ryoho. 2012 May;39(5):809-12.
When performing R-CHOP(rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)for diffuse large B-cell lymphoma(DLBCL), neurotoxicity of vincristine(VCR)is the serious dose-limiting factor.Pregabalin is one of the first-line treatments for painful diabetic peripheral neuropathy in many countries, and we have administered it to relieve the neurotoxicity associated with adverse effects of VCR in a DLBCL patient treated with the R-CHOP regimen.A 49-year-old man with kidney DLBCL had surgery performed.Afterward, the R-CHOP regimen was introduced.In order to relieve the neurotoxicity of VCR, pregabalin was used from day 8 in the second course.The severity of sensory neurotoxicity after the administration of pregabalin was improved from CTCAE(v4.0)grade 3 to grade 1.Therefore, there is a possibility that VCR-induced neurotoxicity is relieved by pregabalin.Further trials are needed to confirm the value of pregabalin.
在采用R-CHOP方案（利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松）治疗弥漫性大B细胞淋巴瘤（DLBCL）时，长春新碱（VCR）的神经毒性是严重的剂量限制因素。在许多国家，普瑞巴林是治疗疼痛性糖尿病周围神经病变的一线药物之一，我们已将其用于缓解一名接受R-CHOP方案治疗的DLBCL患者中与VCR不良反应相关的神经毒性。一名49岁患有肾脏DLBCL的男性接受了手术。术后，采用了R-CHOP方案。为缓解VCR的神经毒性，在第二个疗程的第8天开始使用普瑞巴林。使用普瑞巴林后，感觉神经毒性的严重程度从CTCAE（v4.0）3级改善至1级。因此，普瑞巴林有可能缓解VCR诱导的神经毒性。需要进一步试验来证实普瑞巴林的价值。
